Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

438 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.
van Vollenhoven R, Gunnarsson I. van Vollenhoven R, et al. Arthritis Rheum. 2005 Dec;52(12):4050-1; author reply 4051-2. doi: 10.1002/art.21610. Arthritis Rheum. 2005. PMID: 16320358 No abstract available.
Rituximab-induced long-term remission of membranous lupus nephritis.
Jacobson SH, van Vollenhoven R, Gunnarsson I. Jacobson SH, et al. Among authors: van vollenhoven r. Nephrol Dial Transplant. 2006 Jun;21(6):1742-3. doi: 10.1093/ndt/gfk068. Epub 2006 Jan 23. Nephrol Dial Transplant. 2006. PMID: 16431889 No abstract available.
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B. Szepietowski JC, et al. Among authors: van vollenhoven rf, van hartingsveldt b. Arthritis Rheum. 2013 Oct;65(10):2661-71. doi: 10.1002/art.38091. Arthritis Rheum. 2013. PMID: 23896980 Clinical Trial.
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Petri MA, et al. Among authors: van vollenhoven rf. Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995. Arthritis Rheum. 2013. PMID: 23754628 Clinical Trial.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Petri M, et al. Among authors: van vollenhoven rf. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473. Arthritis Rheum. 2012. PMID: 22553077 Free PMC article.
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE; GL601 Study Group. Petri MA, et al. Arthritis Rheum. 2002 Jul;46(7):1820-9. doi: 10.1002/art.10364. Arthritis Rheum. 2002. PMID: 12124866 Clinical Trial.
Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Jónsdóttir T, et al. Rheumatology (Oxford). 2013 May;52(5):847-55. doi: 10.1093/rheumatology/kes348. Epub 2013 Jan 3. Rheumatology (Oxford). 2013. PMID: 23287364
Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits.
Jónsdóttir T, Sundelin B, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I. Jónsdóttir T, et al. Ann Rheum Dis. 2011 Jun;70(6):1172-3. doi: 10.1136/ard.2010.129288. Epub 2011 Mar 2. Ann Rheum Dis. 2011. PMID: 21367763 Clinical Trial. No abstract available.
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.
van Vollenhoven RF, Houbiers JG, Buttgereit F, In 't Hout J, Boers M, Leij S, Kvien TK, Dijkmans BA, Szczepański L, Szombati I, Sierakowski S, Miltenburg AM. van Vollenhoven RF, et al. Arthritis Rheum. 2010 Feb;62(2):351-8. doi: 10.1002/art.27196. Arthritis Rheum. 2010. PMID: 20112368 Clinical Trial.
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF. Kavanaugh A, et al. Arthritis Rheum. 2009 Nov 15;61(11):1592-600. doi: 10.1002/art.24828. Arthritis Rheum. 2009. PMID: 19877104 Clinical Trial.
438 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback